Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Detalles Bibliográficos
Autores principales: Medisetty, Mahender Kumar, Patel, Atul, Pujari, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883703/
https://www.ncbi.nlm.nih.gov/pubmed/33601033
http://dx.doi.org/10.1016/j.ijid.2021.02.035
_version_ 1783651264766148608
author Medisetty, Mahender Kumar
Patel, Atul
Pujari, Sanjay
author_facet Medisetty, Mahender Kumar
Patel, Atul
Pujari, Sanjay
author_sort Medisetty, Mahender Kumar
collection PubMed
description
format Online
Article
Text
id pubmed-7883703
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78837032021-02-16 Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al Medisetty, Mahender Kumar Patel, Atul Pujari, Sanjay Int J Infect Dis Letter to the Editor Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-04 2021-02-15 /pmc/articles/PMC7883703/ /pubmed/33601033 http://dx.doi.org/10.1016/j.ijid.2021.02.035 Text en © 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Medisetty, Mahender Kumar
Patel, Atul
Pujari, Sanjay
Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_fullStr Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full_unstemmed Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_short Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_sort letter to the editor on “efficacy and safety of favipiravir, an oral rna-dependent rna polymerase inhibitor, in mild-to-moderate covid-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial” by udwadia et al
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883703/
https://www.ncbi.nlm.nih.gov/pubmed/33601033
http://dx.doi.org/10.1016/j.ijid.2021.02.035
work_keys_str_mv AT medisettymahenderkumar lettertotheeditoronefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT patelatul lettertotheeditoronefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT pujarisanjay lettertotheeditoronefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal

Ejemplares similares